{"resourceType":"Observation","id":"TxImp02","meta":{"profile":["http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication"]},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">Poor metabolizer of Voriconazole</div>"},"extension":[{"url":"http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomics-artifact","valueRelatedArtifact":{"type":"citation","url":"https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"}}],"status":"final","category":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/observation-category","code":"laboratory"}]}],"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"therapeutic-implication"}]},"derivedFrom":[{"reference":"Observation/Pgx-geno-1001"}],"component":[{"code":{"coding":[{"system":"http://loinc.org","code":"51963-7"}]},"valueCodeableConcept":{"coding":[{"system":"http://ncimeta.nci.nih.gov","code":"C0393080","display":"voriconazole"}]}},{"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"predicted-therapeutic-implication"}]},"valueCodeableConcept":{"coding":[{"system":"http://loinc.org","code":"LA9657-3","display":"Poor metabolizer"}]}},{"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"conclusion-string"}]},"valueString":"For voriconazole, higher dose-adjusted trough concentrations of voriconazole are expected in individuals with this genotype and may increase the probability of adverse events. An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/."}]}